Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dr. Reddy’s to buy eight US drugs from Teva and Allergan for $350m
The drugs Dr Reddy’s is acquiring are being sold by Teva to secure US antitrust clearance for its $40.5bn acquisition of Allergan’s generic drugs portfolio. The agreement includes
The drugs Dr Reddy’s is acquiring are being sold by Teva to secure US antitrust clearance for its $40.5bn acquisition of Allergan’s generic drugs portfolio. The agreement includes
The company said its decision was based on evidence of tumour-inhibiting activity from early pre-clinical trials with the technology. GBM accounts for 16% of all diagnosed brain cancers
Afferent develops therapeutic candidates targeting the P2X3 receptor to treat common, poorly-managed, neurogenic conditions. The agreement gives Merck access to Afferent’s lead investigational candidate, AF-219, which is a
South African generic-drugs maker Aspen will also pay AstraZeneca royalties and about $250m in additional sales-based installments in the next two years. AstraZeneca’s anaesthetics portfolio includes five local
Erenumab, which is being co-developed with Novartis, was tested at the 70 mg and 140 mg doses in a 12-week, 667-patient phase 2 study of subjects who were
Under the partnership, Ultragenyx will receive an exclusive license to one preclinical Takeda candidate in an unspecified predetermined area of use. Ultragenyx will retain an exclusive option to
Sirukumab is being co-developed by GlaxoSmithKline (GSK) and Janssen Biologics in a partnership that startesd in December 2011. It is a human monoclonal IgG kappa antibody that binds
The primary endpoint was a multicomponent measure assessing enhancement of physical function, cognitive function, and disability. Opicinumab also did not meet the secondary efficacy endpoint in the Phase
The double-blind, placebo-controlled study randomized 153 patients into four treatment arms. All participants were on statin therapy and had LDL-C levels between 70 and 190 mg/dL. At baseline,
The 395-patient study assessed the safety and efficacy of 5 mg and 10 mg of tofacitinib administered twice daily in adult patients with active psoriatic arthritis (PsA) who